IL-15 in CAR engineering: striking an efficacy-safety balance.

IF 12.8 1区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Trends in molecular medicine Pub Date : 2025-06-18 DOI:10.1016/j.molmed.2025.05.014

Yan-Ruide Li, Yichen Zhu, Lili Yang

引用次数: 0

Abstract

Interleukin (IL)-15 engineering in chimeric antigen receptor (CAR)-cell therapy has demonstrated promising antitumor efficacy against both hematological malignancies and solid tumors in recent clinical trials. However, increased cytokine release syndrome (CRS) toxicity is primarily observed in conventional CAR-T cells, underscoring the need to balance safety and efficacy in IL-15-enhanced CAR therapy for clinical application.

查看原文本刊更多论文

IL-15在CAR工程中的应用：达到疗效与安全性的平衡。

在最近的临床试验中，嵌合抗原受体（CAR）细胞治疗中的白细胞介素(IL)-15工程已显示出对血液系统恶性肿瘤和实体肿瘤的有希望的抗肿瘤疗效。然而，增加的细胞因子释放综合征（CRS）毒性主要在常规CAR- t细胞中观察到，这强调了il -15增强CAR- t治疗在临床应用中需要平衡安全性和有效性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Trends in molecular medicine 医学-生化与分子生物学

CiteScore

24.60

自引率

0.00%

发文量

142

审稿时长

6-12 weeks

期刊介绍： Trends in Molecular Medicine (TMM) aims to offer concise and contextualized perspectives on the latest research advancing biomedical science toward better diagnosis, treatment, and prevention of human diseases. It focuses on research at the intersection of basic biology and clinical research, covering new concepts in human biology and pathology with clear implications for diagnostics and therapy. TMM reviews bridge the gap between bench and bedside, discussing research from preclinical studies to patient-enrolled trials. The major themes include disease mechanisms, tools and technologies, diagnostics, and therapeutics, with a preference for articles relevant to multiple themes. TMM serves as a platform for discussion, pushing traditional boundaries and fostering collaboration between scientists and clinicians. The journal seeks to publish provocative and authoritative articles that are also accessible to a broad audience, inspiring new directions in molecular medicine to enhance human health.